Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
about
Insulin receptor substrate-2 is expressed in kidney epithelium and up-regulated in diabetic nephropathyIRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumorsInsulin receptor substrates (IRSs) and breast tumorigenesis.Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation.The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells.IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma.Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancerThe adaptor protein insulin receptor substrate 2 inhibits alternative macrophage activation and allergic lung inflammationInsulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer.Inactivation of RARβ inhibits Wnt1-induced mammary tumorigenesis by suppressing epithelial-mesenchymal transitions.Frontier of epilepsy research - mTOR signaling pathway.PDGF-induced vascular smooth muscle cell proliferation is associated with dysregulation of insulin receptor substrates.RETRACTED: Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis.Bayesian hierarchical structured variable selection methods with application to MIP studies in breast cancerThe insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer.Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic CholangiocarcinomaType 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST.Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.A brain-specific Grb2-associated regulator of extracellular signal-regulated kinase (Erk)/mitogen-activated protein kinase (MAPK) (GAREM) subtype, GAREM2, contributes to neurite outgrowth of neuroblastoma cells by regulating Erk signalingExpression and function of the insulin receptor substrate proteins in cancerLack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancerPrecursor IGF-II (proIGF-II) and mature IGF-II (mIGF-II) induce Bcl-2 And Bcl-X L expression through different signaling pathways in breast cancer cells.Down-regulation of tensin2 enhances tumorigenicity and is associated with a variety of cancersHypoxia regulates insulin receptor substrate-2 expression to promote breast carcinoma cell survival and invasion.Insulin-like growth factors and insulin: at the crossroad between tumor development and longevity.miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2.Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration.MEMO1, a new IRS1-interacting protein, induces epithelial-mesenchymal transition in mammary epithelial cells.Targeting IGF1R pathway in cancer with microRNAs: How close are we ?Insulin receptor substrate 2 and FoxO3a signalling are involved in E-cadherin expression and transforming growth factor-β1-induced repression in kidney epithelial cells.Mutual interaction and reciprocal down-regulation between c-met and insulin receptor substrate-1.Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta.Developmental reprogramming of IGF signaling and susceptibility to endometrial hyperplasia in the rat.Insulin receptor substrate 1 expression enhances the sensitivity of 32D cells to chemotherapy-induced cell death.MiR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells.LXRalpha activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins.Bioactive peptides control receptor for advanced glycated end product-induced elevation of kidney insulin receptor substrate 2 and reduce albuminuria in diabetic mice.
P2860
Q24338974-B51445A5-A122-4B55-988C-09AF2ABC8051Q28288521-3D84C397-F06F-471D-817A-B17232AE0492Q33642166-91015957-8708-4D85-AA08-62E3C0B93729Q33670029-3EEF1DCA-9463-456A-AC33-9D3183D9B8AAQ33745823-5145C708-3FBA-4802-AA39-564AE9188355Q33755364-7A328D12-2B25-4B89-A109-71C98FD80E73Q33757043-8A86D6B5-E4F1-4C2B-8F25-CF3B892EBA6EQ33801131-C778BB7A-F591-4BA9-A617-D8363054DBF5Q33892950-123FFA81-1D7B-4BDD-96C4-57483AF38DB7Q34515985-F693A9FF-F6F2-4538-8F56-A422EA408BCEQ34564798-389E0DB7-8622-4BEB-BDB3-D6056B8764BEQ35014198-28797F58-402B-4CEE-B527-911D0A5F45E7Q35055601-B058B558-94F4-4E12-AF6B-99378F0E3B02Q35097075-92417CC5-9CC5-4354-8303-FF8E51B0ECADQ35101179-F2D1B3EF-0C3E-4B69-B1A1-FAF6DAA566E2Q35124588-5DB75A24-E2D1-4A56-B2F5-F0B9E6EC9963Q35873406-9DB0B6E0-61FF-4380-96C2-CF4990F6E92BQ35917441-7EC97B1F-8D45-41CE-9D72-B8EA01613CDFQ36115675-68BD2E16-77B1-466A-897B-E78DA2E5AF07Q36879136-9EC26F09-1D8C-4FBE-993D-26FD0CFF68D0Q36916389-D7CC21BA-8BCB-4EAC-AFED-5B20F615EB96Q37226266-99A5DCCA-BB9B-42AE-B24D-3383F0E698DFQ37257933-07D6EB5B-7EB9-4C77-8C8C-8121C7C3A01EQ37356570-1C501298-9789-48B3-88F4-FD38E4C99162Q37414445-CF7D5361-BE92-472A-85DF-6B308AF825DAQ37437434-5374684D-ED4F-4E2A-9F4F-ED93004E4750Q37461086-EA55615D-953A-4502-82BD-D6D8EC45D21AQ37994048-E560DC80-EDBF-48A2-A593-533336247EE3Q38870198-AD0724BB-ED5D-457B-B4F5-4632A4AC3186Q38893460-8289346C-B01A-4DFB-A8D4-FCE7A50309CDQ39309649-5489FC61-46A5-4D28-A4B5-DEE9EDD139EEQ39371841-A5F0DFD4-E23E-41E1-A2D3-615EC75C5A72Q39503214-211C0F3F-6C0A-476B-BD32-A457255D67A7Q39688384-36BCC0DB-63A4-4B67-9E37-62A3BA9C95BEQ39887874-BA39938E-90C5-439A-847A-767C2E1ECAE8Q42166312-A7884F07-BC7F-449B-A1AF-7BA4633E7CE8Q42234701-39E1C07D-29B9-4936-8059-735234E4029BQ44117797-87A306C0-A12D-4D53-82D3-2D6F043FF3ADQ45982093-78D4A515-7984-460C-BB13-5924D80A55FCQ46529730-372DE64A-F526-400B-B034-DADB0BDD2994
P2860
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@ast
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@en
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@nl
type
label
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@ast
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@en
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@nl
prefLabel
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@ast
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@en
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@nl
P2093
P3181
P356
P1433
P1476
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
@en
P2093
Leslie M Shaw
Shannon L Gibson
P3181
P356
10.4161/CC.6.6.3987
P407
P577
2007-03-15T00:00:00Z